^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DRD1 antagonist

7d
A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas. (PubMed, Front Pharmacol)
Other interventions that showed efficacy are thiamine (tested also as a prophylactic drug), dexmedetomidine, and hemodialysis. Other pharmaceuticals have been tested in a preclinical setting showing some activity: trifluoperazine, morin, caffeic acid phenethyl ester (CAPE), and alpha lipoic acid (ALA). The aim of this review is to gather the current knowledge about the mechanisms underlying the IIE and the current therapeutic approach and the future perspectives.
Review • Journal
|
GSTP1 (Glutathione S-transferase pi 1) • GSTM1 (Glutathione S-transferase mu 1) • GSTT1 (Glutathione S-transferase theta 1)
|
ifosfamide
17d
New P3 trial
|
dexamethasone • olanzapine • ondansetron
17d
LAMP: Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum (clinicaltrials.gov)
P=N/A, N=125, Recruiting, University of Liverpool | Trial primary completion date: Jul 2025 --> Dec 2025 | Trial completion date: Aug 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
fluphenazine
25d
Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia (clinicaltrials.gov)
P1, N=36, Recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Trial completion date: Jan 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> Jun 2025
Trial completion date • Trial primary completion date
|
olanzapine
1m
Trial completion
|
olanzapine
1m
New P2 trial
|
olanzapine
1m
Trial completion
|
olanzapine
2ms
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects (clinicaltrials.gov)
P1, N=30, Recruiting, Intra-Cellular Therapies, Inc. | N=12 --> 30 | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Mar 2025 --> Sep 2025
Enrollment change • Trial completion date • Trial primary completion date
2ms
New P1 trial
2ms
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine (clinicaltrials.gov)
P=N/A, N=40, Completed, Seattle Institute for Biomedical and Clinical Research | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2024
Trial completion • Trial completion date
|
olanzapine
2ms
Steroid-sparing Therapy (Olanzapine) Versus Dexamethasone-based Therapy for Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov)
P4, N=104, Recruiting, The Guthrie Clinic | Trial completion date: Nov 2024 --> Nov 2029 | Trial primary completion date: Nov 2024 --> Nov 2028
Trial completion date • Trial primary completion date • Head-to-Head
|
olanzapine
3ms
Enhancing Recovery in Early Schizophrenia (clinicaltrials.gov)
P2, N=180, Recruiting, Central Institute of Mental Health, Mannheim | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
Trial completion date • Trial primary completion date
|
olanzapine
3ms
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients (clinicaltrials.gov)
P2, N=150, Terminated, Central Institute of Mental Health, Mannheim | Trial completion date: Jun 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2024 --> Sep 2024; Following the expiry of the original research grant, no follow-up financing could be provided to complete the study.
Trial completion date • Trial termination • Trial primary completion date
|
olanzapine
3ms
Adiponectin, resistin, interleukin-4 and TGF-β2 levels in treatment resistant schizophrenia patients. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry)
We report elevated resistin and IL-4 levels and decreased adiponectin levels in first-episode, treatment resistant schizophrenia patients after clozapine treatment. These findings may be at least partly due to the anti-inflammatory action of clozapine, although sub-clinical metabolic disturbances may also have played a role as far as resistin and adiponectin are concerned. In a subgroup of these patients we report reduced TGF-β2 and adiponectin levels after two unsuccessful trials with risperidone and olanzapine comparing them with the ones of the same subgroup in the drug-naïve phase.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1) • IL4 (Interleukin 4)
|
IL4 elevation
|
olanzapine
3ms
Exercise and Olanzapine-samidorphan (clinicaltrials.gov)
P4, N=30, Not yet recruiting, New York State Psychiatric Institute
New P4 trial
3ms
Repurposing of the Antipsychotic Trifluoperazine Induces SLC7A11/GPX4- Mediated Ferroptosis of Oral Cancer via the ROS/Autophagy Pathway. (PubMed, Int J Biol Sci)
The elevated expression level of GPX4 in oral cancer biopsies was also found to correlate with a poor prognosis. Together, these results provide evidence that TFP selectively induces GPX4-mediated, autophagy-dependent ferroptosis, thereby exerting anti-cancer effects against oral cancer and preventable death.
Journal
|
GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11)
3ms
Melatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine (clinicaltrials.gov)
P=N/A, N=40, Active, not recruiting, Seattle Institute for Biomedical and Clinical Research | N=20 --> 40
Enrollment change
|
olanzapine
4ms
ITI-1284-301: Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder (clinicaltrials.gov)
P2, N=705, Recruiting, Intra-Cellular Therapies, Inc. | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Dec 2026 --> Jun 2027
Trial completion date • Trial primary completion date
4ms
New P2 trial
4ms
Deprescribing Antipsychotics in Long-Term Care (clinicaltrials.gov)
P=N/A, N=6, Completed, McMaster University | Unknown status --> Completed | N=20 --> 6
Trial completion • Enrollment change
|
olanzapine
4ms
OBSERVSPEECH: Voice-Based Biomarkers: a Novel Approach to Monitoring and Predicting Schizophrenia Relapses (clinicaltrials.gov)
P=N/A, N=200, Recruiting, Centre Hospitalier St Anne | Not yet recruiting --> Recruiting
Enrollment open • Adherence
|
olanzapine
4ms
Regulation of ADAM10 activity through microdomain-dependent intracellular calcium changes. (PubMed, Cell Commun Signal)
The calmodulin-inhibitors trifluoperazine and ophiobolin A mediated delayed activation of ADAM10, which apparently did not depend on intracellular Ca2+ in the case of trifluoperazine...Finally, ADAM10 activation was observed after the entry of Ca2+ through certain channels, such as canonical members of transient receptor potential (TRP) channels. Therefore, the opening of particular channels for Ca2+ entry points and subsequent Ca2+ flux as well as the temporal aspects of the consequent increase in Ca2+ levels, must be considered for future therapeutic options involving the increasing or decreasing ADAM10 activity.
Journal
|
ADAM10 (ADAM Metallopeptidase Domain 10)
5ms
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder (clinicaltrials.gov)
P1, N=95, Active, not recruiting, Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
olanzapine
5ms
Aripiprazole, but Not Olanzapine, Alters the Response to Oxidative Stress in Fao Cells by Reducing the Activation of Mitogen-Activated Protein Kinases (MAPKs) and Promoting Cell Survival. (PubMed, Int J Mol Sci)
ARI de-sensitizes Fao cells to stress signaling, while OLA has the opposite effect. These findings contribute to our understanding of the metabolic risks associated with prolonged AAP use and may inform future therapeutic strategies.
Journal
|
STAT3 (Signal Transducer And Activator Of Transcription 3)
|
olanzapine
5ms
Effects of 6-week olanzapine treatment on serum IL-2, IL-4, IL-8, IL-10, and TNF-α levels in drug-naive individuals with first-episode schizophrenia. (PubMed, BMC Psychiatry)
Our results indicate that serum IL-2, IL-8, IL-10, and TNF-α levels may be involved in the pathophysiological mechanisms of schizophrenia and correlate with the effects of olanzapine.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
|
IL10 elevation
|
olanzapine
5ms
Synergistic combination of perphenazine and temozolomide suppresses patient-derived glioblastoma tumorspheres. (PubMed, Neuro Oncol)
The synergistic combination of PER and TMZ has potential as a novel combination treatment strategy for GBM.
Journal
|
DRD2 (Dopamine Receptor D2)
|
temozolomide
5ms
Olanzapine Anorexia Cachexia (clinicaltrials.gov)
P3, N=164, Completed, Cairo University | Recruiting --> Completed
Trial completion
|
olanzapine
6ms
In silico study of some plant compounds as potential anticancer agents targeting MALT1 allosteric domain. (PubMed, J Biomol Struct Dyn)
Our findings from this computational study presents cyanidin (-8.822 kcal/mol) as better binder to the allosteric site of MALT1 based on the molecular docking and pharmacokinetic profiling than thioridazine...Hence, cyanidin is a potential allosteric inhibitor of MALT1. However, an urgent need for in vitro and in vivo validations is required to ascertain the efficacy of cyanidin in the fight against cancer and other MALT1-related diseases.
Journal
|
MALT1 (MALT1 Paracaspase)
6ms
New trial • Adherence
|
olanzapine
6ms
PSD-AOFC: Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (clinicaltrials.gov)
P4, N=60, Completed, All India Institute of Medical Sciences, Bhubaneswar | Recruiting --> Completed
Trial completion
6ms
Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients with Advanced Stage Cancer (clinicaltrials.gov)
P2, N=170, Enrolling by invitation, Englewood Hospital and Medical Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
olanzapine
6ms
Fluspirilene exerts an anti-glioblastoma effect through suppression of the FOXM1-KIF20A axis. (PubMed, Neoplasma)
We investigated fluspirilene, perphenazine, and sulpiride, three classic anti-schizophrenic drugs, as possible anti-GBM agents. In fluspirilene-treated cells, FOXM1 protein was decreased, indicating that KIF20A was downregulated in the presence of the drug due to decreased FOXM1 protein. These results demonstrate that fluspirilene is an effective anti-GBM agent that works by suppressing the FOXM1-KIF20A oncogenic axis.
Journal
|
FOXM1 (Forkhead Box M1) • KIF20A (Kinesin Family Member 20A)
7ms
Trifluoperazine exerts anti-osteosarcoma effect by inducing mitochondria-dependent apoptosis via AKT/TXNIP signaling pathway. (PubMed, Toxicol Appl Pharmacol)
In vivo, TFP inhibited subcutaneous OS cell proliferation and induced OS cell apoptosis without noticeable side effects. In conclusion, our findings imply that TFP is a potential treatment for OS.
Journal
|
TXNIP (Thioredoxin Interacting Protein)
7ms
Trial completion
|
olanzapine
7ms
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC (clinicaltrials.gov)
P2, N=156, Not yet recruiting, Second Affiliated Hospital of Nanchang University
New P2 trial • IO biomarker • Metastases
|
Opdivo (nivolumab) • olanzapine
7ms
Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. (PubMed, Biomed Pharmacother)
These findings suggest that fluphenazine has the potential to be used as an anti-breast cancer drug by inducing cuproptosis. Therefore, this research provides an insight for the development of novel cuproptosis-dependent anti-cancer agents.
Journal
|
FDX1 (Ferredoxin 1)
|
fluphenazine
7ms
Quetiapine Versus Trazadone in Women With Postpartum Depression (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Lawson Health Research Institute
New P1 trial
7ms
Characterization of SUSD3 as a novel prognostic biomarker and therapeutic target for breast cancer. (PubMed, Clin Transl Oncol)
The research emphasizes the significance of SUSD3 as a potential marker for BC, providing insights into the underlying molecular mechanisms implicated in tumorigenesis. SUSD3 holds promise in helping the classification of breast cancer pathological groups, predicting prognosis, and facilitating targeted therapy.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
fulvestrant • fluphenazine • raloxifene hydrochloride